Securities Fraud

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

The case stems from an FDA warning that promotional claims for Anktiva were false or misleading, which drove a roughly 21% stock drop on March 24.